Document text
Principal Investigator: Pardis Christine Sabeti
Organization: BROAD INSTITUTE, INC.
Fiscal Year: 2020
Award: $349,995
Funding agency: National Institute of Allergy and Infectious Diseases
This proposal is intended to develop novel clinical diagnostics for, and increase our understanding of, the
diversity, evolution, and spread of the newly emerged SARS-related coronavirus 2 (SARS-CoV-2) and other
respiratory disease-causing pathogens in the United States.
Coronavirus Disease 2019 (COVID-19) is associated with mild to severe respiratory disease, which can be
fatal. The novel viral etiological agent was first identified in December 2019 in Wuhan City, Hubei Province,
China following an outbreak of pneumonia in individuals associated with a seafood market, and has since
spread globally. Originally named “2019 novel coronavirus”, the virus has since been renamed severe acute
respiratory syndrome-related coronavirus (SARS-CoV-2). As of 10 February 2020, this includes 40,554
confirmed cases and 910 deaths within 25 countries1. There have been 12 confirmed cases of COVID-19 in
the United States2, one of which was identified in Boston, MA in an individual who recently returned from
China3. As public health agencies continue to monitor, track, and attempt to control its spread, it is most crucial
that they are equipped with the most effective tools to detect SARS-CoV-2 and distinguish it from other
common causes of similar respiratory illness.
This proposal addresses the critical gap in clinical diagnostics amidst the quickly moving COVID-19 outbreak
by advancing multiplexed and point of care tools for screening a large number of respiratory disease samples
in a public health lab setting. It builds upon the genomic disease surveillance aims of the Viral project within
our existing Genomic Centers for Infectious Disease (NIAID), but accounts for the increased costs based on
the scale of work related to outbreak response. The tools generated by this project specifically address a
glaring need at the public health laboratory level and have the potential to accelerate their investigative abilities
for undiagnosed respiratory disease.
Terms: <2019 novel coronavirus><2019-nCoV><Address><Assay><Award><Bats><Bioassay><Biologic Assays><Biological Assay><Boston><COVID-19><COVID19><CRISPR><CRISPR/Cas system><Causality><Cell Communication and Signaling><Cell Signaling><Cessation of life><China><Chiroptera><Cities><Clinical><Clustered Regularly Interspaced Short Palindromic Repeats><Cognitive Discrimination><Communities><Complement><Complement Proteins><ConvNet><Coronaviridae><Coronavirus><Data><Death><Devices><Diagnostic><Discriminant Analyses><Discriminant Analysis><Discrimination><Disease Outbreaks><Disease Surveillance><Epidemiology><Etiology><Evaluation><Evolution><Functional Metagenomics><Genetic Alteration><Genetic Change><Genetic defect><Genome><Genomic Centers for Infectious Diseases><Genomics><Glare><Goals><Grippe><HCoV><Human><Hybrids><Illumination><Immune response><Immunological response><Individual><Influenza><Internet><Intracellular Communication and Signaling><Laboratories><Libraries><Lighting><Location><Logistic Regressions><Lung diseases><Mainland China><Measures><Metagenomics><Methods><Modern Man><Monitor><Mutation><NIAID><Names><National Institute of Allergy and Infectious Disease><Oligo><Oligonucleotides><Outbreaks><Pathogenicity><Pneumonia><Population><Process><Province><Public Health><Pulmonary Diseases><Pulmonary Disorder><Reporting><Research Resources><Research Specimen><Resources><Respiratory Disease><Respiratory System Disease><Respiratory System Disorder><Running><SARS><SARS coronavirus disease><SARS-CoV disease><SARS-CoV-2><SARS-CoV2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Sampling><Screening procedure><Sea-Food><Seafood><Sensitivity and Specificity><Severe Acute Respiratory Syndrome><Severe Acute Respiratory Syndrome CoV disease><Severe Acute Respiratory Syndrome coronavirus disease><Severe acute respiratory syndrome coronavirus 2><Signal Transduction><Signal Transduction Systems><Signaling><Site><Specimen><Sum><Technology><Testing><Time><United States><Variant><Variation><Viral><Viral Genome><Virus><WWW><Work><Wuhan coronavirus><base><biological signal transduction><causation><clinical diagnostics><communicable disease diagnosis><computational pipelines><convolutional network><convolutional neural nets><convolutional neural network><corona virus><corona virus disease 2019><coronavirus disease 2019><cost><data sharing><design><designing><diagnostic assay><disease causation><disease of the lung><disorder of the lung><entire genome><epidemiologic><epidemiological><flu infection><full genome><genome mutation><genome sequencing><host response><human CoV><human corona virus><human coronavirus><immunogenicity><immunoresponse><improved><infectious disease diagnosis><influenza infection><insight><interest><iterative design><lung disorder><meetings><metagenome><mobile computing><mobile platform><mobile technology><novel><oligos><parallelization><pathogen><point of care><prototype><respiratory><response><screening tools><tool><viral genomics><virus genome><virus genomics><web><whole genome><world wide web>